BioMarin Pharmaceutical to acquire Inozyme Pharma for $270m.

BioMarin Pharmaceutical, a global biotechnology company, agreed to acquire Inozyme Pharma, a clinical-stage biopharmaceutical company, for $270m. "Today's announcement gives greater hope to patients who may benefit from INZ-701, a potentially transformative therapy that aims to address the underlying causes and systemic impacts of ENPP1 Deficiency. BioMarin has paved the way over the past two and a half decades, successfully launching five first-in-disease enzyme therapies. I'd like to thank the team at Inozyme and our partners for their outstanding work and dedication, as we pass this important potentially life-changing therapy to the leading innovator in genetically defined conditions," Douglas A. Treco, Inozyme CEO and Chairman.